Mark M Awad

Mark M Awad

UNVERIFIED PROFILE

Are you Mark M Awad?   Register this Author

Register author
Mark M Awad

Mark M Awad

Publications by authors named "Mark M Awad"

Are you Mark M Awad?   Register this Author

63Publications

2709Reads

38Profile Views

Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Radiology 2019 Oct 6;293(1):15-29. Epub 2019 Aug 6.

From the Departments of Imaging (H.P., M.N.) and Medical Oncology (M.M.A.), Dana-Farber Cancer Institute, and Departments of Radiology (H.P., H.H., M.N.), Pathology (L.M.S.), and Medicine (M.M.A.), Brigham and Women's Hospital, 450 Brookline Ave, Boston, MA 02215.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019190173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6776234PMC
October 2019

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.

Cancer Immunol Immunother 2019 Jun 15;68(6):917-926. Epub 2019 Mar 15.

Division of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02321-z
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02321-zDOI Listing
June 2019

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.

Abdom Radiol (NY) 2019 May;44(5):1917-1927

Department of Medical Oncology and Department of Medicine, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01935-2DOI Listing
May 2019

BRAF Mutation Class and Clinical Outcomes-Response.

Clin Cancer Res 2019 May;25(10):3189

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0422DOI Listing
May 2019

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Front Oncol 2019 29;9:199. Epub 2019 Mar 29.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450051PMC
March 2019

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Clin Cancer Res 2019 01 17;25(1):158-165. Epub 2018 Sep 17.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2062DOI Listing
January 2019

Authors' Response.

J Thorac Oncol 2018 11;13(11):e237

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.09.015DOI Listing
November 2018

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.

Clin Cancer Res 2018 09 22;24(18):4437-4443. Epub 2018 Mar 22.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0143DOI Listing
September 2018

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.

J Thorac Oncol 2018 08 6;13(8):e131-e133. Epub 2018 Apr 6.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.026DOI Listing
August 2018

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 07 6;13(7):1037-1042. Epub 2018 Apr 6.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.031DOI Listing
July 2018

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

J Clin Oncol 2018 07 10;36(19):1905-1912. Epub 2018 May 10.

Giulia C. Leonardi, Sasha Kravets, Suzanne E. Dahlberg, and Mark M. Awad, Dana-Farber Cancer Institute; Justin F. Gainor and Roxana Azimi, Massachusetts General Hospital; Lydia Gedmintas, Brigham and Women's Hospital, Boston, MA; Mehmet Altan, MD Anderson Cancer Center, Houston, TX; Hira Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Matthew D. Hellmann, Weill Cornell Medical College, and Parker Institute for Cancer Immunotherapy, New York, NY; and Jonathan W. Riess, University of California Davis Comprehensive Cancer Center, Sacramento, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.0305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553840PMC
July 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event.

Cancer Immunol Res 2018 06 5;6(6):630-635. Epub 2018 Apr 5.

Departments of Medical Oncology and Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-17-0715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984707PMC
June 2018

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

J Immunother 2017 Jul/Aug;40(6):249-251

*Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute †Division of Endocrinology, Diabetes and Hypertension ‡Department of Medicine, Brigham and Women's Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000173DOI Listing
March 2018

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.

Clin Cancer Res 2017 Oct 5;23(19):5737-5744. Epub 2017 Jul 5.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-1434DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626605PMC
October 2017

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.

Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.9352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559893PMC
May 2017

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients.

J Immunother Cancer 2016 20;4:84. Epub 2016 Dec 20.

Department of Medical Oncology and Department of Medicine Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA 02215 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0193-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168591PMC
December 2016

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.

Cancer Immunol Res 2016 Apr 10;4(4):289-93. Epub 2016 Feb 10.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818710PMC
April 2016

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

J Clin Oncol 2016 Mar 4;34(7):721-30. Epub 2016 Jan 4.

Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Jennifer C. Heng, Suzanne E. Dahlberg, Pasi A. Jänne, and Peter S. Hammerman, Dana-Farber Cancer Institute; Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Pasi A. Jänne, Peter S. Hammerman, and Lynette M. Sholl, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Suman Verma, ResearchDX, Irvine; and James Christensen, Mirati Therapeutics, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.4600DOI Listing
March 2016

Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.

Authors:
Mark M Awad

J Clin Oncol 2016 Mar 19;34(8):879-81. Epub 2016 Jan 19.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2777DOI Listing
March 2016

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.

Cancer Immunol Res 2016 Jan 20;4(1):12-7. Epub 2015 Nov 20.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Brigham and Women's Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0197DOI Listing
January 2016

Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

J Clin Oncol 2015 Jun 27;33(18):1993-4. Epub 2015 Apr 27.

Dana-Farber Cancer Institute, Boston, MA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.4172DOI Listing
June 2015

Dabrafenib in combination with trametinib for the treatment of metastatic melanoma.

Expert Rev Clin Pharmacol 2015 Jan 4;8(1):25-33. Epub 2014 Dec 4.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2015.974556DOI Listing
January 2015

Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.

J Thorac Oncol 2014 Nov;9(11):1726-8

*Division of Medical Oncology; and †Division of Rheumatology, Allergy, and Immunology; Department of Medicine, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000350DOI Listing
November 2014

ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.

Clin Adv Hematol Oncol 2014 Jul;12(7):429-39

Harvard Medical School and Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215402PMC
July 2014

Tyrosine kinase gene rearrangements in epithelial malignancies.

Nat Rev Cancer 2013 Nov 17;13(11):772-87. Epub 2013 Oct 17.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3612DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902129PMC
November 2013

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

N Engl J Med 2013 09;369(12):1173

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1309091DOI Listing
September 2013

Neutrophil-erythrocyte rosettes in autoimmune hemolytic anemia.

Am J Hematol 2013 Apr 7;88(4):333-4. Epub 2012 Aug 7.

Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23277DOI Listing
April 2013

Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Nat Clin Pract Cardiovasc Med 2008 May 1;5(5):258-67. Epub 2008 Apr 1.

Johns Hopkins University School of Medicine and Johns Hopkins University Cellular and Molecular Medicine Program, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpcardio1182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822988PMC
May 2008

Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2.

Hum Mutat 2006 Nov;27(11):1157

McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/humu.9461
Publisher Site
http://dx.doi.org/10.1002/humu.9461DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799897PMC
November 2006